Epstein-Barr virus antigen peptide-major histocompatibility complex (EBV pMHC)

Epstein-Barr virus (EBV) antigens presented as peptide-major histocompatibility complexes (pMHC) are critical targets for immunotherapy in EBV-associated malignancies and lymphoproliferative disorders (Taylor et al., 2015, PubMed: 25707612). These complexes consist of short viral peptides derived from EBV proteins—such as Latent Membrane Proteins (LMP1, LMP2) or Epstein-Barr Nuclear Antigens (EBNA)—bound within the groove of Human Leukocyte Antigen (HLA) molecules on the surface of infected cells (Long et al., 2011, PubMed: 21148331). Recognition of these pMHCs by the T-cell receptor (TCR) of CD8+ cytotoxic T-lymphocytes triggers a specific immune response aimed at eliminating the infected or transformed cells (Hislop et al., 2007, PubMed: 17591546). In diseases like post-transplant lymphoproliferative disorder (PTLD) and nasopharyngeal carcinoma, the virus maintains a latent infection, expressing specific antigens that can be exploited for therapeutic intervention (Bollard & Heslop, 2016, PubMed: 27161222). Current drug development focuses on adoptive T-cell therapies, such as tabelecleucel (Ebvallo), and engineered TCR-T cells that specifically bind these viral pMHC complexes to restore or enhance the host's anti-viral immunity (Prockop et al., 2020, JCI, PubMed: 31961824). Because these targets are highly specific to infected cells, they offer a pathway for precision oncology with potentially lower systemic toxicity compared to traditional chemotherapy.

Other names

EBV-specific peptide-HLA complexEBV pHLAEpstein-Barr virus-derived peptide-MHC complexEBV antigen-MHC complex

T-cell receptor (TCR) mediated recognition of the viral peptide-MHC complex on the surface of infected cells, leading to cytotoxic T-lymphocyte (CTL) activation, secretion of perforins and granzymes, and targeted lysis of the EBV-infected or transformed cell (Hislop et al., 2007, PubMed: 17591546).